Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

3.3K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Pituitary Immune Environment and Immunotherapy: From Hypophysitis to Pituitary Neuroendocrine Tumors.

Cells·2025
See all related articles

Related Experiment Video

Updated: May 17, 2025

Author Spotlight: A Selective Luciferase-Based Assay for Monitoring ATG4B 27 Activity in Cells
09:51

Author Spotlight: A Selective Luciferase-Based Assay for Monitoring ATG4B 27 Activity in Cells

Published on: June 30, 2023

720

Targeting Autophagy for Pituitary Tumors.

Evan Yin1, Motoyasu Satou2, Toru Tateno1

  • 1Division of Endocrinology and Metabolism, Department of Medicine, University of Alberta, Edmonton, AB T6G 2G3, Canada.

Cancers
|May 14, 2025
PubMed
Summary

Autophagy, a cellular recycling process, plays a complex role in pituitary tumors. Targeting autophagy presents a potential therapeutic strategy for these tumors, requiring further research.

Keywords:
autophagycell proliferationhormone productionpituitary tumors

More Related Videos

Quantitative Analysis of Autophagy using Advanced 3D Fluorescence Microscopy
09:59

Quantitative Analysis of Autophagy using Advanced 3D Fluorescence Microscopy

Published on: May 3, 2013

17.8K
Evaluating Autophagy Levels in Two Different Pancreatic Cell Models Using LC3 Immunofluorescence
08:07

Evaluating Autophagy Levels in Two Different Pancreatic Cell Models Using LC3 Immunofluorescence

Published on: April 28, 2023

1.4K

Related Experiment Videos

Last Updated: May 17, 2025

Author Spotlight: A Selective Luciferase-Based Assay for Monitoring ATG4B 27 Activity in Cells
09:51

Author Spotlight: A Selective Luciferase-Based Assay for Monitoring ATG4B 27 Activity in Cells

Published on: June 30, 2023

720
Quantitative Analysis of Autophagy using Advanced 3D Fluorescence Microscopy
09:59

Quantitative Analysis of Autophagy using Advanced 3D Fluorescence Microscopy

Published on: May 3, 2013

17.8K
Evaluating Autophagy Levels in Two Different Pancreatic Cell Models Using LC3 Immunofluorescence
08:07

Evaluating Autophagy Levels in Two Different Pancreatic Cell Models Using LC3 Immunofluorescence

Published on: April 28, 2023

1.4K

Area of Science:

  • Endocrinology
  • Cell Biology
  • Oncology

Background:

  • Pituitary tumors are classified as functioning or non-functioning based on hormone production.
  • Impaired autophagy, a cellular recycling mechanism, is linked to pituitary tumorigenesis and hormone dysregulation.

Purpose of the Study:

  • To comprehensively review the relationship between autophagy and pituitary tumors.
  • To explore autophagy's dual role in cancer and its specific mechanisms (macroautophagy, mitophagy, crinophagy) in pituitary tumorigenesis.
  • To analyze therapeutic interventions targeting autophagy in pituitary tumor cells.

Main Methods:

  • Literature review of studies on autophagy and pituitary tumors.
  • Analysis of autophagy's role in cancer, pituitary tumorigenesis, and hormone regulation.
  • Examination of therapeutic strategies involving autophagy modulation.

Main Results:

  • Autophagy has a context-dependent dual role in cancer, acting as both a tumor suppressor and promoter.
  • Specific autophagy mechanisms are relevant to pituitary tumor development and hormone regulation.
  • Therapeutic interventions modulating autophagy show potential but require careful consideration due to complexity.

Conclusions:

  • Targeting autophagy is a promising therapeutic avenue for pituitary tumors.
  • Challenges exist in interpreting autophagy activity and its interaction with hormone production.
  • Further research and clinical trials are essential to optimize autophagy-targeted therapies for individual patients.